0001568651FALSE00015686512026-06-042026-06-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 4, 2026
Oscar Health, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware001-4015446-1315570
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

75 Varick Street, 5th Floor
New York, New York 10013
(Address of Principal Executive Offices) (Zip Code)
(646) 403-3677
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbols
Name of each exchange
on which registered
Class A Common Stock, $0.00001 par value per shareOSCRNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.07.
Submission of Matters to a Vote of Security Holders.
On June 4, 2026, Oscar Health, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on April 10, 2026 (the “Record Date”), there were 265,530,268 shares of Class A common stock outstanding, each share being entitled to one vote, and 35,591,356 shares of Class B common stock outstanding, each share of Class B common stock being entitled to 20 votes. At the Annual Meeting, the holders of 820,307,497 votes of the Common Stock were represented in person or by proxy, constituting a quorum.

The stockholders of the Company voted as follows at the Annual Meeting:

Proposal 1 – Election of eight director nominees to serve until the 2027 Annual Meeting:
NomineeVotes FORVotes WITHHELDBroker Non-Votes
Mark T. Bertolini772,818,9261,558,10245,930,469
William J. Gassen III750,059,35424,317,67445,930,469
Joshua Kushner773,650,856726,17245,930,469
Laura Lang773,617,446759,58245,930,469
David Alexander Plouffe770,608,3293,768,69945,930,469
Siddhartha Sankaran771,818,5512,558,47745,930,469
Mario Schlosser773,697,551679,47745,930,469
Vanessa Ames Wittman772,915,6301,461,39845,930,469

Proposal 2 – Advisory vote to approve named executive officer compensation:
Votes FORVotes AGAINSTVotes ABSTAINEDBroker Non-Votes
765,188,3308,859,050329,64845,930,469

Proposal 3 – Ratification of appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2026:
Votes FORVotes AGAINSTVotes ABSTAINEDBroker Non-Votes
819,470,681710,425126,391–

Based on the foregoing votes, the eight director nominees were elected, and Items 2 and 3 were approved.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Oscar Health, Inc.
By:/s/ Adam McAnaney
Name:Adam McAnaney
Title:Chief Legal Officer
Date: June 9, 2026